Skip to main content
Autobound logo

What Bristol Myers Squibb's latest 10-Q says: 8 signals

Bristol Myers Squibb filed its latest 10-Q with the SEC on Jul 30, 2026. It discusses competitor named, compliance burden and data investment.

Public (BMY)Biotechnology Research10,000+ employeesbms.comLinkedIn

Filed
Jul 30, 2026
Filings
2
Signals
19

10-Q · latest 10

What Bristol Myers Squibb's 10-Q filings say

  1. 10-Q

    Filed · 8 signals

    SEC EDGAR

  2. 10-Q

    Filed · 11 signals

    SEC EDGAR

Showing 10 of 19 filing signals. The Signal API returns all of them.

Get them with one API call

Earnings calls

Bristol Myers Squibb earnings headlines

From earnings call transcripts (Signal API type earnings-transcripts).

Earnings call headlines
Call dateWhat the company said
Completed sales field force expansion to support new drug launch.The company has expanded its commercial field force to increase reach and frequency for the Cobenfy launch. This headcount growth creates immediate opportunities for vendors in sales enablement, CRM optimization, training platforms, and field data analytics.
Acquiring Orbital Therapeutics to strengthen cell therapy franchiseThe acquisition of Orbital Therapeutics adds a novel RNA technology platform and an 'off-the-shelf' CAR-T asset, representing a significant investment to lead in autoimmune disease treatments. This M&A activity will require technology and process integration, creating opportunities for consulting and platform vendors.
Recent drug launches for Cobenfy and Qvantig are performing well.The successful launches of two new drugs, Cobenfy and Qvantig, are contributing to revenue growth and require sustained investment in marketing, sales support, patient services, and data analytics to maintain momentum and capture market share.
Struggling to disrupt entrenched physician prescribing behaviors for new drugThe company is focused on disrupting the 'entrenched D2 prescribing behavior' for its new drug, Cobenfy, which requires significant physician education. This market adoption challenge signals a need for solutions related to medical education, key opinion leader (KOL) mapping, and commercial effectiveness analytics.
Building a 'transformational platform' for cancer treatment.The company is making a major strategic bet on radiopharmaceuticals, describing it as a 'transformational platform' built through licensing and acquisitions. This long-term initiative signals sustained investment in R&D, specialized manufacturing, and the underlying technology required to support a new modality.
Driving over $1B in savings via strategic productivity initiative.A major corporate initiative is underway to achieve over $1 billion in net savings, with operating expenses already down $100M in Q3. Companies pursuing large-scale efficiency are prime targets for automation, AI, and analytics solutions that optimize processes and reduce operational costs.

Signal API · MCP

Track Bristol Myers Squibb with the Signal API

One POST /v1/companies/enrich call with bms.com returns Bristol Myers Squibb 10-Q signals (sec-10q), each with its source. Or ask Claude through MCP.

Start Free1,000 free creditsUse it in Claude via MCP

2 credits per signal returned; zero-result calls are free. Endpoint reference

curl -X POST https://signals.autobound.ai/v1/companies/enrich \
  -H "X-API-KEY: $AUTOBOUND_API_KEY" \
  -H "Content-Type: application/json" \
  -d '{"domain":"bms.com","signal_types":["sec-10q"],"limit":20}'

Same industry

10-Q at related companies

Questions about Bristol Myers Squibb 10-Q

When did Bristol Myers Squibb file its latest 10-Q?
Bristol Myers Squibb filed its latest 10-Q on Jul 30, 2026. The one before it was filed on Apr 30, 2026.
What did Bristol Myers Squibb disclose in its latest 10-Q?
From the filing dated Jul 30, 2026: Legacy drug portfolio revenue collapses due to generic erosion; Revlimid sales down 56% YTD.
What did Bristol Myers Squibb say on its recent earnings calls?
Q3 FY2025: Completed sales field force expansion to support new drug launch. (dated Oct 30, 2025).
Where can I read Bristol Myers Squibb's 10-Q filing?
The full filing is on SEC EDGAR: https://www.sec.gov/Archives/edgar/data/14272/000001427226000020/bmy-20260630.htm. This page summarizes what the filing says and links to it.

Source. Quarterly reports (Form 10-Q) filed with the SEC. Every card links to the filing on EDGAR.

Method. Insights are extracted from the filing text and grouped by category. Numbers are quoted from the filing.

Data as of .

How this data is built →Get it from the Signal API →